Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | ECE1 | P42892 | 7/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5822565 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL1898083 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL5970197 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL5735540 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL15004878 | 0.99 | ACE (0.63) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL30997441 | 0.97 | ACE (0.61) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL30903469 | 0.95 | ERAP2 (0.60) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL17941661 | 0.94 | LTA4H (0.59) | ACEERAP2KMT2A | |
| SCHEMBL17941660 | 0.94 | LTA4H (0.59) | ACEERAP2KMT2A | |
| SCHEMBL30284429 | 0.94 | ERAP2 (0.64) | ACEECE1ERAP2ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664262-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-04 | — | — | US | disclosed |
| US-8592607-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-11-26 | — | — | US | disclosed |
| US-8507449-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-13 | — | — | US | disclosed |
| US-8481588-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8476235-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-07-02 | — | — | US | disclosed |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20130045930-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-02-21 | — | — | US | disclosed |
| US-20130045929-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-02-21 | — | — | US | disclosed |
| US-20130005987-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-01-03 | — | — | US | disclosed |
| US-8207217-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC (CA) | 2012-06-26 | — | — | US | disclosed |
| US-20100029742-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-2121728-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121727-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008098355-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008064465-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045930-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | TPH1, TPH2, AADAT | ACE 248/4885ECE1 2368/4885ERAP2 1874/4885 |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ACE 828/4885ECE1 2864/4885ERAP2 2902/4885 |
| US-20100029742-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | TPH1, AADAT, KYNU | ACE 283/4885ECE1 2537/4885ERAP2 2686/4885 |
| US-20130045929-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | TPH1, AADAT, SLC6A4 | ACE 252/4885ECE1 1855/4885ERAP2 2870/4885 |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | DDC, AADAT, GLUL | ACE 381/4885ECE1 2044/4885ERAP2 2964/4885 |
| US-20130005987-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | TPH1, AADAT, SLC6A4 | ACE 252/4885ECE1 1855/4885ERAP2 2870/4885 |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ACE 828/4885ECE1 2864/4885ERAP2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.